Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound (ACCUMEN-POCUS)
Primary Purpose
COPD, CHF, Pneumonia
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Lung point of care ultrasound
PRESUNA software
Sponsored by
About this trial
This is an interventional diagnostic trial for COPD
Eligibility Criteria
Patient Inclusion Criteria:
- 18 years of age or older
- Has a provincial health care number
- Functionally safe to receive HH care or have sufficient caregiving to support them at home
- Stable enough to be cared for at home - stable vital signs and requiring no more than 2 visits per day
- Able and willing to follow a management plan
- Provides consent to receive care on HH
- Diagnosis of CHF and/or COPD that requires HH care
- No painful/broken ribs that could be affected by pressure applied when performing lung POCUS
Patient Exclusion Criteria:
- Not eligible for HH care
- New unstable rib fractures
- Prior history of allergy to ultrasound gel
- Participant refusal to participate in research study
Provider inclusion criteria
- Attending clinician on the home hospital program within the next 3-6 months
- Provides informed consent to participate in the study, including necessary training for the use of POCUS and/or PRESUNA
Provider exclusion criteria
- Not a home hospital clinician
- Refuses to consent for the study / training.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
POCUS-PRESUNA
Standard Care
Arm Description
Daily home hospital care will be enhanced by lung POCUS acquired remotely by community paramedics or in-person by physicians, and interpreted by physicians. They will then document their findings on PRESUNA to obtain a longitudinal record that enables monitoring of trends to support clinical decision-making.
Standard home hospital care
Outcomes
Primary Outcome Measures
Length of stay
Length of stay for index Home Hospital admission
Secondary Outcome Measures
Patient outcome - Time to resolution of infection
return to baseline oxygen saturation and normalization of white blood cell count
Patient outcome - time to decongestion
absence of crackles and baseline oxygen saturation on lung examination
Patient outcome - rate of change in NT-BNP
Difference between NT-BNP on admission and at time of decongestion over total number of days
Patient outcome - Admission to facility living
Proportion of patients in each study arm that required admission to facility living (eg: long-term care, supportive living) after their index admission
Patient outcome - Escalation of care
Incidence rate ratio for frequency with which patients are transferred back to the bricks and mortar hospital from the home hospital.
Patient outcome - Adverse events
Frequency and severity of adverse events (venous thromboembolism, new infections, falls, delirium)
Patient outcome - Mortality
Date and cause of mortality of occurrence of mortality
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Mobility
The ability to mobilize is rated by patients on a scale from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Activities of daily living
Ability to perform activities of daily living rated by patients from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Pain and discomfort
The intensity of pain or discomfort is rated by patients from 1 to 5 (1=none, 2= slight , 3= moderate , 4=severe, 5=extreme).
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Self care
Ability to perform self-care rated from 1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Anxiety and Depression
Patients rate whether they feel anxious or depressed from 1-5 (1=no, 2= slightly, 3= moderately, 4=severely, 5=extremely).
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Index Score
The index score is computed using the EQ-5D calculator that uses the scores of the individual dimensions (mobility, self-care, activities of daily living, pain and discomfort, anxiety and depression); Scores range between 5-25 with higher scores indicating a worse outcome
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) Visual Analogue Scale (EQ-VAS)
Participant asked to rate both verbally and visually "where [they] would put [their] health today" on a scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine)
Patient experience
Survey measuring experience with clinical care and various technologies employed by the Home Hospital (digital remote patient monitoring, videoconferencing, as well as POCUS for the intervention arm). This survey was developed by the study team. Responses to questions were either, "yes", "yes, to some extent", "no", and "unsure".
Provider experience
Surveys including experience providing care for patients on each study arm and experience with various technologies employed in the home hospital program (digital remote patient monitoring, videoconferencing, as well as POCUS and PRESUNA for the intervention arm). This survey was developed by the study team. Responses were on a Likert scale, which included "strongly disagree", "disagree", "neither agree/nor disagree", "agree" and "strongly agree"
Healthcare utilization cost - Diagnostic testing
Cost of Diagnostic testing
Healthcare utilization - Incidence rate ratio of acute care days pre/during/post
Incidence rate ratio of acute care days in the bricks and mortar hospital 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
Healthcare utilization - Incidence rate ratio of ED/Urgent Care visits pre/during/post
Incidence rate ratio of ED and urgent care visits- 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
Cost analysis
Incremental effectiveness ratio for the index admission
Cost analysis
Incremental effectiveness ratio for healthcare utilization post-discharge
Full Information
NCT ID
NCT05423652
First Posted
May 5, 2022
Last Updated
December 5, 2022
Sponsor
Michelle Grinman
Collaborators
PRESUNA, Institute of Health Economics, Canada, Alberta Boehringer Ingelheim Collaboration
1. Study Identification
Unique Protocol Identification Number
NCT05423652
Brief Title
Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound
Acronym
ACCUMEN-POCUS
Official Title
Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 10, 2023 (Anticipated)
Primary Completion Date
January 10, 2024 (Anticipated)
Study Completion Date
January 10, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Michelle Grinman
Collaborators
PRESUNA, Institute of Health Economics, Canada, Alberta Boehringer Ingelheim Collaboration
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Single-center, two-arm, parallel, randomized controlled trial comparing enhanced daily assessments for patients with COPD and/or CHF using point of care ultrasound with PRESUNA software (POCUS-PRESUNA) versus standard care provided by home-based acute care through a tertiary acute care medical teaching hospital. The objectives are to evaluate POCUS-PRESUNA on improving patient experience, provider experience, improve healthcare utilization/costs, and to test the feasibility of incorporating longitudinal POCUS assessments in home-based acute care via remotely acquired images by non-physicians.
Detailed Description
PRESUNA, a new medical software platform that supports clinicians in optimizing their use of POCUS for CHF and COPD patients in the community, is designed to enhance clinical decision-making and long-term monitoring of patients with CHF and COPD. The aim is to more precisely identify changes in the lungs in order to proactively treat exacerbations and confirm treatment responses. It will also enable practitioners to share information from each scan visually and in a standard format in order to track changes longitudinally. This is expected to reduce potentially avoidable hospitalizations and increase patient quality of life in the community.
This study will implement the use of POCUS enhanced by PRESUNA software in the clinical practice of clinicians on a home hospital (HH) program at a tertiary teaching hospital in Calgary, Alberta. On this home hospital, patients are seen and examined either by home visiting community paramedics who consult with the physician, or in-person by physicians in the home hospital clinic space when expedited diagnostic imaging or investigations are required.
Objective:
To perform a randomized control trial comparing patients with COPD and/or CHF admitted to the HH who will undergo usual care versus usual care enhanced with POCUS and PRESUNA.
Methods:
Practitioner Recruitment Home hospital clinicians will be provided information about this study in order to obtain informed consent for participation in the study. Physicians who are already POCUS experts will provide informed consent to undergo training on how to use PRESUNA software and to incorporate POCUS into their home hospital care for intervention study patients. Non-POCUS expert clinicians (community paramedics, some of the physicians and nurses) will provide informed consent to undergo group POCUS training and subsequent individual training sessions in order to enable them to become proficient at using POCUS. They will also consent to being trained on how to use PRESUNA software, as well as incorporating POCUS and PRESUNA into their home hospital care for intervention arm patients.
Patient Recruitment Patients admitted to HH with CHF and/or COPD will be approached to participate in the research study by the Nurse Navigator or Research Assistant. Those that provide informed consent will be randomized (1:1) to the intervention (POCUS-PRESUNA enhanced HH care) versus control group (usual HH care).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD, CHF, Pneumonia
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
44 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
POCUS-PRESUNA
Arm Type
Experimental
Arm Description
Daily home hospital care will be enhanced by lung POCUS acquired remotely by community paramedics or in-person by physicians, and interpreted by physicians. They will then document their findings on PRESUNA to obtain a longitudinal record that enables monitoring of trends to support clinical decision-making.
Arm Title
Standard Care
Arm Type
No Intervention
Arm Description
Standard home hospital care
Intervention Type
Device
Intervention Name(s)
Lung point of care ultrasound
Other Intervention Name(s)
POCUS
Intervention Description
Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
Intervention Type
Other
Intervention Name(s)
PRESUNA software
Intervention Description
PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
Primary Outcome Measure Information:
Title
Length of stay
Description
Length of stay for index Home Hospital admission
Time Frame
From the date of admission to discharge from the index admission, assessed up to 1 year
Secondary Outcome Measure Information:
Title
Patient outcome - Time to resolution of infection
Description
return to baseline oxygen saturation and normalization of white blood cell count
Time Frame
Assessed up to 24 months after infection identified
Title
Patient outcome - time to decongestion
Description
absence of crackles and baseline oxygen saturation on lung examination
Time Frame
Assessed up to one year after congestion identified
Title
Patient outcome - rate of change in NT-BNP
Description
Difference between NT-BNP on admission and at time of decongestion over total number of days
Time Frame
Change from admission to when decongestion occurred, assessed up to 12 months
Title
Patient outcome - Admission to facility living
Description
Proportion of patients in each study arm that required admission to facility living (eg: long-term care, supportive living) after their index admission
Time Frame
From date and time of discharge from index admission, assessed up to 12 months
Title
Patient outcome - Escalation of care
Description
Incidence rate ratio for frequency with which patients are transferred back to the bricks and mortar hospital from the home hospital.
Time Frame
From date of randomization until the patient is discharged from the index admission (assessed up to 12 months).
Title
Patient outcome - Adverse events
Description
Frequency and severity of adverse events (venous thromboembolism, new infections, falls, delirium)
Time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first until the patient is discharged from the hospital (assessed up to 12 months).
Title
Patient outcome - Mortality
Description
Date and cause of mortality of occurrence of mortality
Time Frame
From date of randomization until the date of death, assessed up to 12 months
Title
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Mobility
Description
The ability to mobilize is rated by patients on a scale from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
Time Frame
At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Title
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Activities of daily living
Description
Ability to perform activities of daily living rated by patients from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
Time Frame
At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Title
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Pain and discomfort
Description
The intensity of pain or discomfort is rated by patients from 1 to 5 (1=none, 2= slight , 3= moderate , 4=severe, 5=extreme).
Time Frame
At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Title
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Self care
Description
Ability to perform self-care rated from 1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity
Time Frame
At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Title
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Anxiety and Depression
Description
Patients rate whether they feel anxious or depressed from 1-5 (1=no, 2= slightly, 3= moderately, 4=severely, 5=extremely).
Time Frame
At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Title
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Index Score
Description
The index score is computed using the EQ-5D calculator that uses the scores of the individual dimensions (mobility, self-care, activities of daily living, pain and discomfort, anxiety and depression); Scores range between 5-25 with higher scores indicating a worse outcome
Time Frame
At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Title
Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) Visual Analogue Scale (EQ-VAS)
Description
Participant asked to rate both verbally and visually "where [they] would put [their] health today" on a scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine)
Time Frame
At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Title
Patient experience
Description
Survey measuring experience with clinical care and various technologies employed by the Home Hospital (digital remote patient monitoring, videoconferencing, as well as POCUS for the intervention arm). This survey was developed by the study team. Responses to questions were either, "yes", "yes, to some extent", "no", and "unsure".
Time Frame
Upon discharge from the Home Hospital (up to 7 business days post-discharge)
Title
Provider experience
Description
Surveys including experience providing care for patients on each study arm and experience with various technologies employed in the home hospital program (digital remote patient monitoring, videoconferencing, as well as POCUS and PRESUNA for the intervention arm). This survey was developed by the study team. Responses were on a Likert scale, which included "strongly disagree", "disagree", "neither agree/nor disagree", "agree" and "strongly agree"
Time Frame
Within 1 week of being on the Hospital at Home service
Title
Healthcare utilization cost - Diagnostic testing
Description
Cost of Diagnostic testing
Time Frame
Between the date and time of hospital admission to up to 3 months post-discharge
Title
Healthcare utilization - Incidence rate ratio of acute care days pre/during/post
Description
Incidence rate ratio of acute care days in the bricks and mortar hospital 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
Time Frame
90 days before randomization until 90 days after index admission (assessed up to 15 months)
Title
Healthcare utilization - Incidence rate ratio of ED/Urgent Care visits pre/during/post
Description
Incidence rate ratio of ED and urgent care visits- 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
Time Frame
90 days before, during and 90 days after index admission
Title
Cost analysis
Description
Incremental effectiveness ratio for the index admission
Time Frame
From date of admission until the date of discharge from the index admission, assessed up to 12 months").
Title
Cost analysis
Description
Incremental effectiveness ratio for healthcare utilization post-discharge
Time Frame
From date of discharge from index admission, assessed up to 90 days.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Patient Inclusion Criteria:
18 years of age or older
Has a provincial health care number
Functionally safe to receive HH care or have sufficient caregiving to support them at home
Stable enough to be cared for at home - stable vital signs and requiring no more than 2 visits per day
Able and willing to follow a management plan
Provides consent to receive care on HH
Diagnosis of CHF and/or COPD that requires HH care
No painful/broken ribs that could be affected by pressure applied when performing lung POCUS
Patient Exclusion Criteria:
Not eligible for HH care
New unstable rib fractures
Prior history of allergy to ultrasound gel
Participant refusal to participate in research study
Provider inclusion criteria
Attending clinician on the home hospital program within the next 3-6 months
Provides informed consent to participate in the study, including necessary training for the use of POCUS and/or PRESUNA
Provider exclusion criteria
Not a home hospital clinician
Refuses to consent for the study / training.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michelle Grinman, MD FRCPC MPH
Phone
403.943.3889
Email
michelle.grinman@ucalgary.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Steve Reid, BEng
Phone
403.305.7295
Email
steve.reid@presuna.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Grinman, MD FRCPC MPH
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound
We'll reach out to this number within 24 hrs